Since studies identified PLA2 inhibitors as therapeutic targets to reduce COVID-19 mortality [34, 50], future research could address therapy that upregulates MBOAT7 activity as a complimentary strategy to inhibitors of PLA2 in order to restore normal Lands’ cycle homeostasis and minimize inflammation or CS. Here, MBOAT7 is linked to COVID-19.